Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?

Sadeleştirilmiş öğe sayfası
dc.contributor.authorCetin, Bulent
dc.contributor.authorWabl, Chiara A.
dc.contributor.authorGumusay, Ozge
dc.date.accessioned2025-10-16T15:16:03Z
dc.date.issued2022
dc.identifier.doi10.2217/fon-2022-0668
dc.identifier.otherWOS:000918715700001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6607
dc.publisherTAYLOR \& FRANCIS LTD
dc.sourceFUTURE ONCOLOGY
dc.subjectadvanced prostate cancer
dc.subjecthomologous recombination repair
dc.subjectPARP inhibitors
dc.titleShould one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?
dc.typeEditorial Material

Dosyalar

Koleksiyonlar

WOS